Dr. Damon R. Demady is a Senior Managing Scientist at ToxStrategies in the Biopharmaceutical and Pharmaceutical Practice. He is a pharmacologist and preclinical safety assessment expert with 17 years of industry experience in several key areas of drug development, including pharmacology, toxicology, ADME, safety, and risk assessment, through all phases of drug development (discovery, preclinical and clinical, registration, and post marketing). He has worked in preclinical development spanning startups to large pharma. Dr. Demady has written peer-reviewed publications, as well as non-clinical sections and clinical risk assessments for drug applications and submissions, including INDs, NDAs, BLAs, investigator brochures, product labels, patient consent forms, and carcinogenicity proposals and assessments. His experience includes numerous interactions with the FDA and international regulatory bodies. In addition, he has had responsibility for due diligence and business development activities throughout his time in industry, helping to evaluate strategic opportunities for in-licensing, acquisitions, and partnerships. Dr. Demady’s drug development experience includes small molecules, biologics, ADCs, cell therapies, and antibody-based products in a wide array of therapeutic areas. These include oncology (particularly immune therapy), neurology/pain, ophthalmology, inflammation, and cardiovascular disease, all spanning numerous indications.